Skip to main content
TipRanks
Go Ultimate75% OFF

Zura Bio (94E) Stock Price & Analysis

3 Followers

94E Stock Chart & Stats

€1.12-€0.14(-11.11%)
At close: 5:30 PM GMT+1
€4€4.5Sep 9Oct 2Oct 13Oct 14Nov 9
Day’s Range
EUR 1.12 - EUR 1.12
52-Week Range
EUR 1.06 - EUR 6.00
Previous Close
EUR 1.26
Volume
N/A
Average Volume (3M)
93
Market Cap
EUR 108.37M
Enterprise Value
EUR 343.63M
Total Cash (Recent Filing)
EUR 187.65M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.91
Next Earnings
Mar 31, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

A zero-debt capital structure reduces near-term solvency and refinancing pressure while preserving flexibility to fund clinical development. Positive equity provides an additional financial buffer, although continued losses could gradually erode this strength if operating performance does not improve.

Clinical Funding Visibility

Cash runway through at least 2028 gives Zura the ability to advance multiple clinical programs toward important readouts without an immediately stated funding deadline. This supports continuity of execution and improves visibility across the next several development milestones.

Pipeline Progress

Progress in systemic sclerosis and preparation for the polymyalgia rheumatica study preserve multiple potential development paths despite the hidradenitis setback. Advancing programs across indications can diversify clinical outcomes and maintain strategic options over the medium term.

Bears Say

No Commercial Revenue

Zura has not yet demonstrated commercial revenue to offset research and corporate spending, while its TTM loss widened materially from 2025. This pre-revenue model leaves near-term financial performance dependent on clinical progress rather than an established earnings base.

Heavy Cash Burn

Deeply negative operating and free cash flow indicate that losses are translating directly into substantial funding needs. Even with a strong current cash position, sustained burn can reduce financial flexibility over time and increase reliance on future capital or successful clinical advancement.

Phase 2 Program Failure

The Phase 2 miss removes one development path and reduces the value of tibulizumab in hidradenitis suppurativa, while also exposing clinical execution and efficacy risk. Discontinuation narrows the pipeline and increases dependence on systemic sclerosis and polymyalgia rheumatica outcomes.

Zura Bio News

94E FAQ

What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was €1.06 and its highest was €6.00 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is €108.37M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 135 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Oct 27, 2026. The company reported -€0.179 earnings per share for the quarter, beating the consensus estimate of -€0.183 by €0.004.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.18.
How many shares outstanding does Zura Bio have?
Zura Bio has 96,325,410 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -€0.179 in its last earnings report, beating expectations of -€0.183. Following the earnings report the stock price went up 6.757%.
Which hedge fund is a major shareholder of Zura Bio?
Hedge funds hold Zura Bio shares: the largest hedge-fund position in Zura Bio is 630,449,728 shares, and hedge funds increased their holdings by 28.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology